Shares of Prenetics Global Limited (NASDAQ:PRE – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the five brokerages that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $34.25.
A number of brokerages have recently weighed in on PRE. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Prenetics Global in a research note on Tuesday, April 21st. Benchmark increased their price target on shares of Prenetics Global from $30.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday.
Read Our Latest Report on Prenetics Global
Key Headlines Impacting Prenetics Global
- Positive Sentiment: Prenetics said its IM8 business secured $1 billion in non-dilutive financing, which could support growth without issuing new shares and signals strong outside confidence in the subsidiary’s outlook. Prenetics’ IM8 Secures $1 Billion Non-Dilutive Financing as Revenue Outlook Rises
- Positive Sentiment: Management also highlighted that PRE continues to exceed expectations and is receiving preferential financing, reinforcing the idea that the company may have better operating momentum than the market had assumed. PRE Continues to Exceed Expectations and Receive Preferential Financing
- Positive Sentiment: CEOs comments about using the financing to fuel IM8’s growth suggest the company has a clearer path to scaling a high-growth subsidiary, which can improve investor sentiment around future revenue expansion. Prenetics CEO on securing 1 billion funding to fuel subsidiary IM8’s growth
- Neutral Sentiment: Sidoti and other analysts maintained a generally constructive stance overall, with a consensus recommendation of “Moderate Buy,” but the reports mostly focused on model updates rather than a major new catalyst. Prenetics Global Limited (NASDAQ:PRE) Given Consensus Recommendation of Moderate Buy by Analysts
- Negative Sentiment: Sidoti cut earnings estimates for several periods, including 2026-2027 quarters and FY2027, which could weigh on the stock because it implies weaker near-term profitability than previously expected.
Prenetics Global Stock Down 3.3%
Shares of PRE stock opened at $18.29 on Friday. The stock has a fifty day moving average of $18.70 and a 200 day moving average of $18.47. Prenetics Global has a 52 week low of $7.18 and a 52 week high of $23.63. The firm has a market capitalization of $308.55 million, a price-to-earnings ratio of -3.99 and a beta of 0.26.
Prenetics Global (NASDAQ:PRE – Get Free Report) last issued its quarterly earnings data on Wednesday, June 10th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.07). Prenetics Global had a negative net margin of 62.45% and a negative return on equity of 20.33%. The company had revenue of $35.95 million for the quarter, compared to analysts’ expectations of $36.00 million. Equities research analysts anticipate that Prenetics Global will post -1.26 earnings per share for the current year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the company. Wells Fargo & Company MN bought a new position in shares of Prenetics Global in the 4th quarter worth approximately $47,000. State of Wyoming purchased a new position in shares of Prenetics Global in the 1st quarter valued at approximately $48,000. JPMorgan Chase & Co. bought a new stake in shares of Prenetics Global during the third quarter valued at approximately $65,000. Manatuck Hill Partners LLC bought a new stake in shares of Prenetics Global during the fourth quarter valued at approximately $170,000. Finally, T3 Companies LLC purchased a new stake in Prenetics Global in the fourth quarter worth $170,000. Hedge funds and other institutional investors own 25.01% of the company’s stock.
About Prenetics Global
Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.
Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.
Featured Stories
- Five stocks we like better than Prenetics Global
- Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop
- Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs?
- The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story
- Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Receive News & Ratings for Prenetics Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prenetics Global and related companies with MarketBeat.com's FREE daily email newsletter.
